Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your voice may reveal hidden liver risks

NCT ID NCT05425316

Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether speech features—like how people sound and what they say—can help detect or predict confusion caused by liver disease (hepatic encephalopathy). Researchers recorded speech tasks from 251 participants with cirrhosis and tracked their thinking skills and confusion episodes over time. The goal is to find a simple, non-invasive way to monitor brain health in people with liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

251 people

The number who actually took part.

Started

Oct 2021

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population consists of adult outpatients who are evaluated at the University of Michigan Hepatology Clinic.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Patients with Cirrhosis: * Cirrhosis, as diagnosed by imaging, elastography, biopsy, or decompensation * Able to provide informed consent in English Exclusion Criteria for Patients with Cirrhosis: * Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia * Prior stroke or Transischemic Attack (TIA) * English not primary language for communication Inclusion Criteria for Patients without Cirrhosis: * Able to provide informed consent in English * Fibroscan with stiffness \<7 kPa Exclusion Criteria for Patients without Cirrhosis: * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \>5 times the upper limit of normal in the last year * History of cirrhosis by imaging or histology or clinical decompensation * Neurodegenerative disorder (other than hepatic encephalopathy) including Alzheimer's disease and dementia * Prior stroke or TIA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hepatic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic encephalopathy

Contacts and locations

Locations

  • University of Michigan Hepatology and Transplant Clinic

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.